Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country/Region, 2017, 2022 & 2028

2.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type

2.2.1 1g/20ml

2.2.2 1.25g/25ml

2.2.3 2.5g/50ml

2.2.4 5g/100ml

2.2.5 10g/200ml

2.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

2.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

2.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue and Market Share by Type (2017-2022)

2.3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2017-2022)

2.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Market Share by Application (2017-2022)

2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue and Market Share by Application (2017-2022)

2.5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Application (2017-2022)

3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company

3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Breakdown Data by Company

3.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Company (2020-2022)

3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2020-2022)

3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Company (2020-2022)

3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2020-2022)

3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2020-2022)

3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company

3.4 Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Location Distribution

3.4.2 Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Geographic Region

4.1 World Historic Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Geographic Region (2017-2022)

4.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Geographic Region

4.2 World Historic Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country/Region (2017-2022)

4.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Country/Region (2017-2022)

4.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Country/Region

4.3 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.4 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.5 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.6 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

5 Americas

5.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country

5.1.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

5.1.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

5.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

5.3 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region

6.1.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022)

6.1.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022)

6.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

6.3 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country

7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country

8.1.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

8.1.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

8.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

8.3 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

10.3 Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

10.4 Industry Chain Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors

11.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer

12 World Forecast Review for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Geographic Region

12.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Forecast by Region

12.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Region (2023-2028)

12.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Type

12.7 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Application

13 Key Players Analysis

13.1 Boya-Bio

13.1.1 Boya-Bio Company Information

13.1.2 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Boya-Bio Main Business Overview

13.1.5 Boya-Bio Latest Developments

13.2 Beijing Tiantan Biological Products

13.2.1 Beijing Tiantan Biological Products Company Information

13.2.2 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Beijing Tiantan Biological Products Main Business Overview

13.2.5 Beijing Tiantan Biological Products Latest Developments

13.3 Hualan Bio

13.3.1 Hualan Bio Company Information

13.3.2 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Hualan Bio Main Business Overview

13.3.5 Hualan Bio Latest Developments

13.4 Guangdong Shuagnlin Bio-pharmacy

13.4.1 Guangdong Shuagnlin Bio-pharmacy Company Information

13.4.2 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Guangdong Shuagnlin Bio-pharmacy Main Business Overview

13.4.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments

13.5 Weiguang Biological

13.5.1 Weiguang Biological Company Information

13.5.2 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Weiguang Biological Main Business Overview

13.5.5 Weiguang Biological Latest Developments

13.6 Sinopharm

13.6.1 Sinopharm Company Information

13.6.2 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Sinopharm Main Business Overview

13.6.5 Sinopharm Latest Developments

13.7 Shanghai RAAS

13.7.1 Shanghai RAAS Company Information

13.7.2 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Shanghai RAAS Main Business Overview

13.7.5 Shanghai RAAS Latest Developments

13.8 CTBB

13.8.1 CTBB Company Information

13.8.2 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 CTBB Main Business Overview

13.8.5 CTBB Latest Developments

13.9 Nanyue Biopharming

13.9.1 Nanyue Biopharming Company Information

13.9.2 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Nanyue Biopharming Main Business Overview

13.9.5 Nanyue Biopharming Latest Developments

14 Research Findings and Conclusion

Table 1. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of 1g/20ml

Table 4. Major Players of 1.25g/25ml

Table 5. Major Players of 2.5g/50ml

Table 6. Major Players of 5g/100ml

Table 7. Major Players of 10g/200ml

Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 9. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & ($ million)

Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2022)

Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2017-2022) & (US$/Unit)

Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)

Table 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022)

Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2022)

Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Application (2017-2022) & (US$/Unit)

Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Company (2020-2022) & (K Units)

Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2020-2022)

Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2020-2022) ($ Millions)

Table 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2020-2022)

Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company (2020-2022) & (US$/Unit)

Table 23. Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Producing Area Distribution and Sales Area

Table 24. Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered

Table 25. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Geographic Region (2017-2022) & (K Units)

Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Geographic Region (2017-2022)

Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Geographic Region (2017-2022) & ($ millions)

Table 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Geographic Region (2017-2022)

Table 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country/Region (2017-2022) & (K Units)

Table 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country/Region (2017-2022)

Table 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country/Region (2017-2022) & ($ millions)

Table 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country/Region (2017-2022)

Table 36. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)

Table 37. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2017-2022)

Table 38. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & ($ Millions)

Table 39. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2017-2022)

Table 40. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 41. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

Table 42. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)

Table 43. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Table 44. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units)

Table 45. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)

Table 46. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & ($ Millions)

Table 47. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2017-2022)

Table 48. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 49. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

Table 50. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)

Table 51. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Table 52. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)

Table 53. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2017-2022)

Table 54. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & ($ Millions)

Table 55. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2017-2022)

Table 56. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 57. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

Table 58. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)

Table 59. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Table 60. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)

Table 61. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2017-2022)

Table 62. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & ($ Millions)

Table 63. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2017-2022)

Table 64. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 65. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

Table 66. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)

Table 67. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Table 68. Key Market Drivers & Growth Opportunities of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Table 69. Key Market Challenges & Risks of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Table 70. Key Industry Trends of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Table 71. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List

Table 74. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer List

Table 75. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Region (2023-2028) & (K Units)

Table 76. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Forecast by Region

Table 77. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2023-2028) & ($ millions)

Table 78. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Region (2023-2028)

Table 79. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)

Table 80. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & ($ millions)

Table 81. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Region (2023-2028) & (K Units)

Table 82. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2023-2028) & ($ millions)

Table 83. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)

Table 86. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & ($ millions)

Table 87. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Type (2023-2028) & (K Units)

Table 88. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Type (2023-2028)

Table 89. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 90. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Type (2023-2028)

Table 91. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Application (2023-2028) & (K Units)

Table 92. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Application (2023-2028)

Table 93. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 94. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Application (2023-2028)

Table 95. Boya-Bio Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 96. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 97. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 98. Boya-Bio Main Business

Table 99. Boya-Bio Latest Developments

Table 100. Beijing Tiantan Biological Products Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 101. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 102. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 103. Beijing Tiantan Biological Products Main Business

Table 104. Beijing Tiantan Biological Products Latest Developments

Table 105. Hualan Bio Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 106. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 107. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 108. Hualan Bio Main Business

Table 109. Hualan Bio Latest Developments

Table 110. Guangdong Shuagnlin Bio-pharmacy Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 111. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 112. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 113. Guangdong Shuagnlin Bio-pharmacy Main Business

Table 114. Guangdong Shuagnlin Bio-pharmacy Latest Developments

Table 115. Weiguang Biological Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 116. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 117. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 118. Weiguang Biological Main Business

Table 119. Weiguang Biological Latest Developments

Table 120. Sinopharm Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 121. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 122. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 123. Sinopharm Main Business

Table 124. Sinopharm Latest Developments

Table 125. Shanghai RAAS Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 126. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 127. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 128. Shanghai RAAS Main Business

Table 129. Shanghai RAAS Latest Developments

Table 130. CTBB Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 131. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 132. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 133. CTBB Main Business

Table 134. CTBB Latest Developments

Table 135. Nanyue Biopharming Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 136. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 137. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 138. Nanyue Biopharming Main Business

Table 139. Nanyue Biopharming Latest Developments

List of Figures

Figure 1. Picture of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of 1g/20ml

Figure 10. Product Picture of 1.25g/25ml

Figure 11. Product Picture of 2.5g/50ml

Figure 12. Product Picture of 5g/100ml

Figure 13. Product Picture of 10g/200ml

Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type in 2021

Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2022)

Figure 16. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Hospital

Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Hospital (2017-2022) & (K Units)

Figure 18. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Clinic

Figure 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Clinic (2017-2022) & (K Units)

Figure 20. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Others

Figure 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Others (2017-2022) & (K Units)

Figure 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Figure 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application in 2021

Figure 24. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market by Company in 2021 ($ Million)

Figure 25. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company in 2021

Figure 26. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Geographic Region (2017-2022)

Figure 27. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Geographic Region in 2021

Figure 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)

Figure 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country/Region in 2021

Figure 30. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 31. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 ($ Millions)

Figure 32. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 33. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 ($ Millions)

Figure 34. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 35. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 ($ Millions)

Figure 36. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 37. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 ($ Millions)

Figure 38. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2021

Figure 39. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2021

Figure 40. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 41. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 42. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 43. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 44. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region in 2021

Figure 45. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Regions in 2021

Figure 46. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 47. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 48. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 49. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 50. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 51. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 52. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2021

Figure 53. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2021

Figure 54. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 55. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 56. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 57. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 58. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 59. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2021

Figure 60. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2021

Figure 61. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 62. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 63. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 64. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 65. GCC Country Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 ($ Millions)

Figure 66. Manufacturing Cost Structure Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in 2021

Figure 67. Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 68. Industry Chain Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles